NewLink axes 100 staffers, shrinks pipeline in wake of a PhIII debacle
A little more than two months after NewLink Genetics $NLNK was slammed by the Phase III failure of its pancreatic cancer vaccine algenpantucel-L, the Ames …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
